A dual-effect polymer micelle composite hydrogel and its preparation method and application
Through PEG-modified lenalidomide and hescarin polymer micelle composite hydrogel, the high toxicity and slow efficacy of drugs in the treatment of rheumatoid arthritis are solved, and the response in the inflammatory joint cavity is achieved Sexual release significantly improves therapeutic effect and bioavailability.
Patent Information
- Application Number
- CN202310427424.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-04-20
- Publication Date
- 2024-11-08
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing treatment methods for rheumatoid arthritis have problems such as high toxicity, slow efficacy, poor tolerance and high economic burden, and lack effective drugs to control synovial inflammation and prevent joint bone damage.
Using PEG modified lenalidomide and hescarinidine as model drugs, a dual-effect polymer micelle composite hydrogel was prepared to achieve inflammation Responsive release of drugs in the joint cavity, exerting the dual effects of anti-inflammatory and inhibiting angiogenesis.
It significantly reduces drug toxicity, improves therapeutic effect, delays drug release, improves bioavailability, and shows lower drug toxicity and better treatment effects in the body.
Smart Images

Figure CN116650401B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of nano preparations, and in particular to a method for preparing a dual-effect polymer micelle composite hydrogel. Background Art
[0002] Rheumatoid arthritis (RA) is a chronic autoimmune disease with a prevalence of about 1%. RA is accompanied by pathological features such as inflammatory cell infiltration, synovial tissue hyperplasia, and destruction of cartilage and bone around joints. When the disease worsens, it will further affect the quality of life and even lead to disability, resulting in a decrease in the patient's quality of life and social participation, thus bringing a greater burden to the family and society.
[0003] Clinically, the treatment of RA mainly includes surgical treatment and drug treatment. Surgical treatment has a narrow scope of application, is traumatic and expensive, so the treatment of RA is still mainly drug treatment. The "2018 China Rheumatoid Arthritis Diagnosis and Treatment Guidelines" pointed out that RA cannot be cured, and disease remission or reduced activity is the treatment that meets the standard. Common treatment drugs for RA mainly include non-steroidal anti-inflammatory drugs, anti-rheumatic drugs, glucocorticoids and biological agents. Although these drugs have certain therapeutic effects, they also have corresponding defects and shortcomings. For example, although non-steroidal anti-inflammatory drugs can quickly relieve inflammation and pain, they are accompanied by a variety of related adverse reactions and have no inhibitory effect on the development of the disease. Anti-rheumatic drugs that improve the condition have a strong anti-inflammatory effect and can delay or even hinder the progression of the disease, but they are slow to take effect and poorly tolerated by patients. Glucocorticoids also have the advantages of inhibiting the progression of the disease and preventing bone destruction, but they are prone to dependence and are accompanied by serious adverse reactions. Although biological agents are quick to take effect and have high safety, they can be used to treat patients who are ineffective with traditional therapies; but they are expensive, have a high burden on patients, and have shortcomings such as poor absorption and high risk of infection. Diverse genetic factors and complex environmental factors are jointly involved in the pathogenesis of RA. Therefore, there is currently no medication regimen or effective measure to cure RA at home and abroad.
[0004] Synovial inflammation is the main feature of RA. The release of proinflammatory cytokines and matrix metalloproteinases can cause joint bone damage. Therefore, it is extremely urgent to find drugs that can effectively control RA synovitis. Inhibiting endothelial cell migration and reducing the level of proinflammatory cytokines may inhibit the formation of synovial blood vessels, thereby further preventing the occurrence and development of RA. Summary of the invention
[0005] The purpose of the present invention is to provide a dual-effect polymer micelle composite hydrogel and a preparation method and application thereof. The dual-effect polymer micelle composite hydrogel exhibits a significant therapeutic effect on rheumatoid arthritis.
[0006] In order to achieve the above object, the present invention adopts the following technical solution:
[0007] In a first aspect of the present invention, a method for preparing a dual-effect polymer micelle composite hydrogel is provided, the method comprising:
[0008] S1. Chemically linking the lenalidomide API and the hesperidin API with terminal-modified polyethylene glycol, respectively, to obtain PEG-modified lenalidomide (LND-PEG) and PEG-modified hesperidin (HSN-PEG), respectively, and dissolving the LND-PEG and HSN-PEG together in dichloromethane to obtain a prodrug mixed solution;
[0009] S2, dissolving the lenalidomide API and the hesperidin API in dichloromethane to obtain a drug solution; dissolving the terminal-modified polyethylene glycol in dichloromethane to obtain a carrier solution; mixing the drug solution and the carrier solution, and heating them in a water bath at 38-42° C. to react, to obtain a dual-drug loaded micelle solution (L / H-PMs);
[0010] S3, after the prodrug mixed solution and the dual-drug loaded micelle solution are mixed, β-sodium glycerophosphate is added to dissolve, thereby obtaining a β-sodium glycerophosphate mixed solution;
[0011] S4, adding the β-sodium glycerophosphate mixed solution dropwise to the chitosan solution after ice bathing to obtain a gel-like dual-effect polymer micelle composite hydrogel LP / HP / L / H-PMs@Gel.
[0012] Further, in said S1,
[0013] The mass ratio of the terminal-modified polyethylene glycol, lenalidomide API, and hesperidin API is 1:1-1.5:1-1.5:
[0014] The LND-PEG and HSN-PEG are dissolved together in dichloromethane, and the mass volume ratio of the LND-PEG, HSN-PEG and dichloromethane is (4-6) mg: (4-6) mg: (4-6) mL.
[0015] Further, in said S2,
[0016] The mass ratio of the lenalidomide raw material, the hesperidin raw material and the terminal-modified polyethylene glycol is 1:1:3.5-4, the mass fraction of the drug solution is 5%, and the mass fraction of the carrier solution is 8.75%-10%.
[0017] Further, in said S3,
[0018] The volume ratio of the prodrug mixed solution to the dual-drug loaded micelle solution is 1:1;
[0019] The sodium β-glycerophosphate is added, and the mass ratio of the sodium β-glycerophosphate added to the polyethylene glycol with modified terminal groups is 2.5-3.5:1.
[0020] Further, in said S4,
[0021] The volume ratio of the sodium beta-glycerophosphate mixed solution to the chitosan solution is 1:2.5-3.5.
[0022] In the second aspect of the present invention, a dual-effect polymer micelle composite hydrogel prepared by the method is provided.
[0023] Furthermore, the raw materials for preparing the dual-effect polymer micelle composite hydrogel include L / H-PMs, LND-PEG, HSN-PEG, chitosan and sodium β-glycerophosphate; the mass ratio of the components is L / H-PMs: LND-PEG: HSN-PEG: chitosan: sodium β-glycerophosphate = 1:1:1:2:5-7.
[0024] In the third aspect of the present invention, provided is the use of the dual-effect polymer micelle composite hydrogel in the preparation of a drug for treating rheumatoid arthritis.
[0025] One or more technical solutions in the embodiments of the present invention have at least the following technical effects or advantages:
[0026] 1. The present invention uses lenalidomide and hesperidin as model drugs for the treatment of RA. After being modified with PEG, they are respectively formed into two pH-sensitive prodrugs that can be responsively released in the inflammatory joint cavity of RA. Together with the API encapsulated by polymer micelles, they are encapsulated in chitosan injectable hydrogels to construct a dual-effect polymer micelle composite hydrogel LP / HP / L / H-PMs@Gel, thereby achieving effective treatment of RA. Compared with the API and a single preparation, the composite hydrogel LP / HP / L / H-PMs@Gel has lower toxicity and better therapeutic effect on rheumatoid arthritis.
[0027] 2. The present invention successfully prepared a dual-effect polymer micelle composite hydrogel LP / HP / L / H-PMs@Gel loaded with dual-drug polymer micelles and dual prodrugs. After the drug delivery system is injected into the articular cavity, the polymer micelles and dual prodrugs responsively release lenalidomide and hesperidin at the site of inflammation, playing a dual role of both anti-inflammatory and inhibiting angiogenesis, reducing drug toxicity while showing a significant therapeutic effect on rheumatoid arthritis. The successful preparation of the dual-effect polymer micelle composite hydrogel provides a reference for the practical application of this type of complex.
[0028] 3. The dual-effect polymer micelle composite hydrogel LP / HP / L / H-PMs@Gel provided by the present invention is a transparent light yellow flowing gel with a porous three-dimensional structure. The equilibrium swelling rate at 37°C is 1285.46%. It has a drug sustained release effect and a higher cumulative release rate under acidic conditions.
[0029] In the red blood cell hemolysis experiment, the hemolysis rate of each group of preparations was less than 5%, ensuring the safe implementation of subsequent in vivo experiments; compared with free LND and HSN, the cytotoxicity of LP / HP / L / H-PMs@Gel was significantly reduced; the combination of two drugs enhanced the in vitro anti-inflammatory effect of LP / HP / L / H-PMs@Gel; in the chicken embryo chorioallantoic membrane experiment, LP / HP / L / H-PMs@Gel loaded with LND showed a strong inhibitory effect on angiogenesis; compared with normal macrophages, the uptake rate of LP / HP / L / H-PMs@Gel by macrophages activated by LPS was significantly increased.
[0030] The results of pharmacokinetic experiments showed that the dual-effect polymer micelle composite hydrogel can delay drug release in vivo after intra-articular injection and improve the bioavailability of lenalidomide and hesperidin. Fluorescence in vivo imaging experiments also demonstrated the effects of LP / HP / L / H-PMs@Gel in prolonging efficacy and reducing toxicity.
[0031] In vivo pharmacodynamic experiments showed that compared with other drug treatment groups, LP / HP / L / H-PMs@Gel showed lower drug toxicity and better therapeutic effect on rheumatoid arthritis. BRIEF DESCRIPTION OF THE DRAWINGS
[0032] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the accompanying drawings required for use in the description of the embodiments will be briefly introduced below. Obviously, the accompanying drawings in the following description are some embodiments of the present invention. For ordinary technicians in this field, other accompanying drawings can be obtained based on these accompanying drawings without paying any creative work.
[0033] Figure 1Schematic diagram of the dual-effect polymer micelle composite hydrogel LP / HP / L / H-PMs@Gel injected into the joint cavity to treat rheumatoid arthritis. PEG-modified pH-sensitive prodrugs (LP and HP) are combined with polymer micelles (LP / HP / L / H-PMs) loaded with lenalidomide (L) and hesperidin (H), which are encapsulated together in an injectable hydrogel (LP / HP / L / H-PMs@Gel) and locally administered into the inflamed joint cavity of RA to responsively release drugs, achieving effective treatment of RA. LND(L): lenalidomide; HSN(H): hesperidin; LND-PEG(LP): lenalidomide modified with polyethylene glycol; HSN-PEG(HP): hesperidin modified with polyethylene glycol; L / H-PMs: polymer micelles loaded with lenalidomide and hesperidin; LP / HP / L / H-PMs: polymer micelles loaded with pH-sensitive prodrugs (LP and HP) jointly loaded with lenalidomide (L) and hesperidin (H); LP / HP / L / H-PMs@Gel: dual-effect polymer micelle composite hydrogel.
[0034] Figure 2 Compound LND-PEG 2000 and HSN-PEG 2000 Synthesis route of LND and mPEG. 2000 -CHO generates LND-PEG under the catalysis of glacial acetic acid 2000 , (B) HSN and mPEG 2000 -NHNH2 reacts in ethanol to form HSN-PEG 2000 .
[0035] Figure 3 The in vitro characterization results of the dual-effect polymer micelle composite hydrogels. (A) Gel formation state and SEM results, (B) equilibrium swelling rate, (C) cumulative release rate of LND, (D) cumulative release rate of HSN.
[0036] Figure 4 The FTIR spectra of CS, β-GP and dual-effect polymer micelle composite hydrogels.
[0037] Figure 5 The results of in vitro hemolysis of erythrocytes of different preparations. Different preparations such as LND, HSN, LP, HP, L / H-PMs, BlankPMs, Blank Gel and LP / HP / L / H-PMs@Gel were mixed with the erythrocyte suspension of healthy SD rats and incubated at 37°C. (A) Hemolysis after incubation and centrifugation, (B) Hemolysis rate results of different preparations. The results are expressed as mean ± standard deviation (n = 3).
[0038] Figure 6The cytotoxicity results of RAW264.7. The in vitro cytotoxicity of different preparations was determined by MTT assay after incubation for (A) 24 h, (B) 48 h, and (C) 72 h, respectively; RAW264.7 cells were incubated with Blank Gel, LND, HSN, LND+HSN, LP, HP, L-PMs, H-PMs, L / H-PMs, L / H-PMs@Gel, and LP / HP / L / H-PMs@Gel at different concentrations. * P<0.05, ** P<0.01, *** P < 0.001 and **** P<0.0001 was used to evaluate the significant difference between each group and the LND+HSN group. The results were expressed as mean±standard deviation (n=3).
[0039] Figure 7 The results of ELISA kits to measure the content of related cytokines after each group of preparations were co-incubated with RAW264.7 cells for 24 hours. (A) IL-10, (B) IL-12; ** P<0.01, *** P < 0.001, **** P < 0.0001 was used to evaluate the differences in the effects of each group of preparations and the Control group on cytokine levels; #### P<0.0001 was used to evaluate the difference in the effects on cytokine levels between the LND+HSN group and the LP / HP / L / H-PMs@Gel group. The results are expressed as mean ± standard deviation (n=3).
[0040] Figure 8 The results of the effects of different preparations on the neovascularization of chick embryo chorioallantoic membrane. The chick embryo chorioallantoic membrane was incubated with different preparations such as Saline, LND, HSN, LND+HSN, LP, HP, LP+HP, L / H-PMs, Blank PMs, Blank Gel, L / H-PMs@Gel, LP / HP@Gel, LP / L / H-PMs@Gel, HP / L / H-PMs@Gel and LP / HP / L / H-PMs@Gel. After intervention with different preparations, (A) the growth and development of neovascularization of chick embryo chorioallantoic membrane, (B) the number of neovascularization, and (C) the vessel area ratio. * P<0.05, ** P<0.01, *** P < 0.001 and **** P<0.0001 was used to evaluate the significant difference between each group and the Saline group. The results were expressed as mean ± standard deviation (n=3).
[0041] Fig. 9The results of RAW264.7 cells taking different fluorescent agents. (A) Normal RAW264.7 cells and (B) M1 RAW264.7 cells generated after LPS stimulation were incubated with L / H-PMs, L / H-PMs@Gel and LP / HP / L / H-PMs@Gel labeled with coumarin-6 green fluorescence at 37°C for 2h, 4h and 6h, respectively, and then observed and photographed with a laser confocal microscope. Image pro plus was used to perform semi-quantitative analysis of the fluorescence intensity of (C) and (D), and the results are expressed as mean ± standard deviation (n = 3). * P<0.05, ** P<0.01, *** P < 0.001 and **** P < 0.0001 was used to evaluate the significant difference between different preparation groups at the same time point. #### P<0.0001 was used to evaluate the significant differences between LP / HP / L / H-PMs@Gel at different time points.
[0042] Fig.10 The results of in vivo pharmacokinetic metabolism. CIA rats were injected intra-articularly with LND+HSN, LP+HP, L / H-PMs, L / H-PMs@Gel and LP / HP / L / H-PMs@Gel, and the drug concentrations in plasma were detected at different time points (A) LND, (B) HSN. The results are expressed as mean ± standard deviation (n = 3).
[0043] Fig.11 The results of in vivo fluorescence imaging of CIA model rats. Four fluorescent preparations, DiR, L / H-PMs, L / H-PMs@Gel and LP / HP / L / H-PMs@Gel, were injected into the joint cavity. The small animal in vivo imaging device was used to observe the (A) in vivo fluorescence distribution of rats at 0.5h, 4h, 8h and 12h after administration, and (B) the fluorescence distribution of in vitro visceral and joint tissues 12h later. ImageJ was used to semi-quantitatively analyze the fluorescence intensity of (C) in vivo joints and (D) visceral tissues. #### P < 0.0001 was used to evaluate the statistical difference between each group and the Blank group. * P<0.05, ** P<0.01, **** P<0.0001 was used to evaluate the statistical difference between each group and the LP / HP / L / H-PMs@Gel group. The results are expressed as mean±standard deviation (n=3).
[0044] Fig.12The therapeutic effects of the CIA model rats after the last intra-articular injection of each preparation. (A) Hind limb status, (B) body weight change, (C) foot volume change, (D) ankle joint diameter change and (E) arthritis index score of SD rats. ** P<0.01, *** P < 0.001 and **** P<0.0001 was used to evaluate the statistical difference between the Saline group and the other groups. The results are expressed as mean±standard deviation (n=5).
[0045] Fig.13 The results of immune organ coefficients, liver toxicity and cytokine levels in SD rats after intra-articular injection of each group of preparations. (A) Spleen coefficient, (B) Thymus coefficient, (C) ALT, (D) AST, (E) IL-1β, (F) TNF-α. #### P<0.0001 was used to evaluate the different treatment effects between each group and the Saline group. ** P<0.01, *** P < 0.001, **** P<0.0001 was used to evaluate the different treatment effects between the free bulk drug group and the LP / HP / L / H-PMs@Gel group. The results are expressed as mean ± standard deviation (n=3).
[0046] Fig.14 Micro-CT scans and bone-related quantitative index test results. (A) Micro-CT scans, (B) BMD, (C) Tb.Th, (D) Tb.Sp, (E) Tb.N, (F) BS / BV, (G) BV / TV. #### P<0.0001 was used to evaluate the different treatment effects between each group and the Saline group. * P<0.5, ** P<0.01, *** P < 0.001, **** P<0.0001 was used to evaluate the different treatment effects between the free bulk drug group LND+HSN and the LP / HP / L / H-PMs@Gel group. The results are expressed as mean ± standard deviation (n=3). DETAILED DESCRIPTION
[0047] The present invention will be described in detail below in conjunction with specific implementations and examples, and the advantages and various effects of the present invention will be more clearly presented. It should be understood by those skilled in the art that these specific implementations and examples are used to illustrate the present invention, rather than to limit the present invention.
[0048] Throughout the specification, unless otherwise specifically stated, the terms used herein should be understood as meanings commonly used in the art. Therefore, unless otherwise defined, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art to which the present invention belongs. In the event of a conflict, the present specification takes precedence.
[0049] Unless otherwise specified, various raw materials, reagents, instruments and equipment used in the present invention can be purchased from the market or obtained by existing methods.
[0050] The present application will be described in detail below in combination with examples, comparative examples and experimental data. The terminal group-modified polyethylene glycol (mPEG-CHO) in the examples of the present invention was purchased from Xi'an Ruixi Biotechnology Co., Ltd., with the item number R-CWN-316; the terminal group-modified polyethylene glycol (mPEG-NHNH2) was purchased from Xi'an Ruixi Biotechnology Co., Ltd., with the item number R-CWN-01.
[0051] Example 1. Preparation and characterization of dual-effect polymer micelle composite hydrogel
[0052] 1. Synthesis and verification of PEG-modified lenalidomide (LND-PEG)
[0053] according to Figure 2 Prepare LND-PEG (LP) according to the synthetic route shown in A. Accurately weigh 50 mg of terminal-modified polyethylene glycol (mPEG-CHO) and 55 mg of lenalidomide API, place them in a 50 mL volumetric flask containing 10 mL of anhydrous ethanol, add 0.5 mL of glacial acetic acid dropwise while stirring to accelerate the reaction, and react for about 12 h under heating conditions at 70 °C in a water bath.
[0054] 2. Synthesis and verification of PEG-modified hesperidin (HSN-PEG)
[0055] according to Figure 2 The synthetic route shown in B is to prepare HSN-PEG (HP), accurately weigh 110 mg of hesperidin API and 100 mg of terminal-modified polyethylene glycol (mPEG-NHNH2), and heat in anhydrous ethanol in a water bath to react overnight.
[0056] 3. Preparation and characterization of dual-drug loaded polymer micelles (L / H-PMs)
[0057] 1. Preparation of L / H-PMs
[0058] Accurately weigh 5 mg of lenalidomide (LND, L) and hesperidin (HSN, H) into an EP tube, add 2 mL of dichloromethane, and dissolve by ultrasonication. In another EP tube, accurately weigh 17.9 mg of mPEG 2000 -PLA 2000, add 2mL of dichloromethane and shake to dissolve. Heat a volumetric flask containing 7.06mL of ultrapure water to 40.5℃ in a water bath, add the drug and carrier mixture solution dropwise, and stir while dripping. After 4h, remove the excess dichloromethane by rotary evaporation, and after making up the volume, the micelle solution containing lenalidomide LND and hesperidin HSN is obtained, that is, the micelle solution containing dual drugs (L / H-PMs). Blank PMs are prepared in the same way.
[0059] The dual-drug loaded polymer micelles (L / H-PMs) and PEG-modified lenalidomide (LND-PEG) are dissolved together in dichloromethane to obtain a prodrug mixed solution.
[0060] 2. Morphological investigation of L / H-PMs
[0061] The prepared Blank PMs and L / H-PMs were diluted to a certain concentration of polymer micelle solution as needed, and their morphology was observed using a transmission electron microscope. An appropriate amount of solution was dropped onto the coated copper mesh, left to stand for 3 minutes, and excess liquid was removed with filter paper; it was stained with 2% uranyl acetate, dried naturally for 15 minutes, and then the micelle morphology was photographed using a transmission electron microscope.
[0062] 4. Preparation and characterization of dual-effect polymer micelle composite hydrogel
[0063] 1. Preparation of LP / HP / L / H-PMs@Gel
[0064] Weigh 400 mg of chitosan and place it in a 50 mL volumetric flask containing 18 mL (0.1 mol / L) hydrochloric acid, stir while adding, and dissolve under magnetic stirring for 4 to 8 hours to prepare a 2% (w / v) chitosan solution. Take 600 mg of sodium β-glycerophosphate and dissolve it in 2 mL of the mixed solution of the prodrug mixed solution and the dual-drug micelle solution (L / H-PMs), after ice bathing for 15 minutes, add the sodium β-glycerophosphate solution dropwise to the 2% chitosan solution at a volume ratio of 1:3, and stir slowly to obtain a gel-like dual-effect polymer micelle composite hydrogel LP / HP / L / H-PMs@Gel.
[0065] Meanwhile, L / H-PMs@Gel, LP / HP@Gel, LP / L / H-PMs@Gel, and HP / L / H-PMs@Gel were prepared according to the above method for subsequent experiments.
[0066] 2. Morphological analysis of LP / HP / L / H-PMs@Gel
[0067] After freeze-drying the prepared gel-like dual-effect polymer micelle composite hydrogel LP / HP / L / H-PMs@Gel, its morphology was characterized by field emission scanning electron microscopy. The SEM results of the dual-effect polymer micelle composite hydrogel are shown in Figure 3 As shown in A, the prepared injectable hydrogel is translucent light yellow and has certain fluidity. This indicates that after adding β-GP, the hydroxyl and amino groups on the CS molecular chain are cross-linked with it through hydrogen bonds and van der Waals forces, and finally present a uniformly distributed three-dimensional network structure, providing a large amount of storage space for polymer micelles and dual-effect prodrugs.
[0068] 3. Evaluation of swelling properties of LP / HP / L / H-PMs@Gel
[0069] The swelling property of the dual-effect polymer micelle composite hydrogel was evaluated by weighing method. The prepared gel-like dual-effect polymer micelle composite hydrogel LP / HP / L / H-PMs@Gel was freeze-dried to constant weight; placed in pure water at 37°C, taken out and wiped dry after a certain interval, weighed, and the swelling rate (%) was calculated according to Formula 1:
[0070] SR(%)=(m1-m0) / m0 (Formula 1)
[0071] m1: The mass (g) of the gel after being placed in pure water and wiping off the surface moisture.
[0072] m0: mass of the gel after drying to constant weight (g).
[0073] The swelling kinetics curve of the dual-effect polymer micelle composite hydrogel at 37°C is shown in Figure 3 As shown in Figure B, its equilibrium swelling ratio is 1285.46%. As time goes by, the swelling ratio of the gel gradually increases, and at about 3 hours, the swelling ratio tends to be balanced.
[0074] 4. Evaluation of in vitro drug release behavior of LP / HP / L / H-PMs@Gel
[0075] 5 mL of the dual-effect polymer micelle composite hydrogel and the methanol mixture containing the same amount of LND and HSN were measured and placed in dialysis bags with a molecular weight cutoff of 3KD. Finally, they were placed in 200 mL of PBS solutions with pH 4.5 and pH 7.4, respectively. At a certain interval, 2 mL of the solution was taken and the content of LND and HSN was determined by HPLC, so as to calculate their cumulative release rate.
[0076] The cumulative release rates of LND and HSN from the injectable hydrogels at pH 4.5 and 7.4 were as follows: Figure 3C and 3D. Under neutral and acidic conditions, LND and HSN in the API combination group were released rapidly without significant differences. However, L / H-PMs can release LND and HSN more slowly under neutral and acidic conditions. The three-dimensional porous structure of the hydrogel further promotes the sustained release of the drug; when the pH is 7.4, the two pH-sensitive prodrugs encapsulated in the hydrogel cannot be hydrolyzed into two APIs after release, so the cumulative release rates of LND and HSN are low; under acidic conditions, the pH-sensitive prodrugs are hydrolyzed and broken after release, and the cumulative release rates of LND and HSN are high.
[0077] 5. LP / HP / L / H-PMs@Gel FTIR spectral analysis
[0078] The prepared dual-effect polymer micelle composite hydrogel was freeze-dried and its structure was characterized by Fourier transform infrared spectrometer. Figure 4 It can be seen that at 1629.5cm -1 and 1536.8cm -1 At 1110.3cm, they are the absorption peaks of -C=O and NH in CS. In β-GP, 1110.3cm -1 、1054.7cm -1 PO4 3- In the spectrum of CS / β-GP injectable hydrogel, NH in CS and OH in β-GP interact to form hydrogen bonds, so the superimposed stretching vibration absorption peak of OH and NH becomes 3205.5 cm -1 -C=O stretching vibration absorption peak (1656.3cm -1 ) and -NH deformation vibration absorption peak (1555.3cm -1 ) are red-shifted, indicating that NH in CS binds to OH and PO4 in β-GP, respectively. 3- Formation of hydrogen bonds and complexes. In summary, the formation of CS / β-GP injectable hydrogels is due to the change of the intermolecular forces and conformation of CS after mixing with β-GP.
[0079] 6. Solubility determination
[0080] The drug powders of LND and HSN, and the freeze-dried powders of L / H-PMs and LP / HP / L / H-PMs@Gel were dissolved in 10 mL of different solvents (pure water, methanol, and PBS with a pH of 7.4), dissolved by ultrasound, centrifuged at 2780×g for 15 min, filtered, and tested according to the chromatographic conditions. The chromatographic peak areas of LND and HSN were recorded, and the equilibrium solubility of each group of drugs was calculated. All data in this study were expressed as mean ± standard deviation (Mean ± SD), and the data were statistically analyzed using one-way analysis of variance in GraphPad Prism 8.0 software. If P < 0.05, it was considered to be significantly different. The solubility results of LND and HSN in different preparations in various solvents are shown in Tables 1 and 2.
[0081] Table 1 Solubility results of LND in different preparations in various solvents (n=5)
[0082]
[0083]
[0084] Table 2 Solubility results of HSN in different preparations in various solvents (n=5)
[0085]
[0086] As can be seen from the above, free LND is very slightly soluble in pure water, methanol and PBS, and LND encapsulated by polymer micelles is slightly soluble in pure water, methanol and PBS. LND in the dual-drug polymer micelle composite hydrogel is also slightly soluble in various solvents, but the solubility value is significantly increased. Similarly, the solubility trend of free HSN and HSN in the two groups of preparations is basically consistent with that of LND. The above results show that PEG modification and polymer micelle encapsulation can significantly improve the solubility of raw drugs.
[0087] Experimental Example 1: In vitro experimental study of dual-effect polymer micelle composite hydrogel
[0088] 1. In vitro hemolysis test
[0089] Take normal rat whole blood, centrifuge at 500×g until the supernatant is colorless and clear, collect the red blood cell sediment at the bottom, and prepare it into a 2% (v / v) red blood cell suspension. According to the preparation methods under 3.5.1 and 3.6.1 in Chapter 1, prepare three different concentrations of LND, HSN, LP, HP, L / H-PMs, Blank PMs, BlankGel, and LP / HP / L / H-PMs@Gel at 20μg / mL, 80μg / mL, and 200μg / mL, respectively. After mixing each group of preparations with the red blood cell suspension, incubate in a 37℃ water bath for 3h, centrifuge at 900×g for 10min, and take 100μL of the supernatant in a 96-well plate. At the same time, physiological saline and ultrapure water were used as negative and positive controls, respectively. The OD value was measured at a wavelength of 545nm using an enzyme marker, and the hemolysis rate was calculated according to Formula 2.
[0090] Hemolysis rate (%) = (sample OD value - negative control OD value) / (positive control OD value - negative control OD value)
[0091] (Formula 2)
[0092] Depend on Figure 5 B It can be seen that the hemolysis rate of red blood cells in each group of preparations at three different concentrations is less than 5%, which is within the safe range and has good blood compatibility, which can ensure the safe implementation of subsequent in vivo joint cavity injection experiments.
[0093] 2. Cytotoxicity assay
[0094] RAW264.7 cells from normal mice were diluted to a concentration of 3×10 5 Cell suspension of 100 μL per well of 96-well plate was inoculated at 37°C and 5% CO2. After the cells attached to the wall, 100 μL of drugs of different concentrations (Blank Gel, LND, HSN, LND+HSN, LP, HP, L-PMs, H-PMs, L / H-PMs, L / H-PMs@Gel, LP / HP / L / H-PMs@Gel) were added to make the final concentrations (20, 40, 80, 160, 200 μg / mL), and 3 replicates were set at the same concentration. A blank culture medium group and a 0 drug addition group were set. After incubation for 24h, 48h, and 72h, the solution was aspirated and discarded, PBS was added for washing 3 times, 100 μL of 10% MTT culture medium solution was added, and the cells were incubated for another 4h. The solution was aspirated and discarded, 150 μL of DMSO was added to each well, and the cells were shaken at 37°C for 10min. The OD value was measured with an enzyme-labeled instrument at 570 nm, and the cell activity was calculated according to Formula 3:
[0095] Cell activity (%) = (A (加药) -A (空白) ) / (A(0加药) -A (空白) )×100% (Formula 3)
[0096] A (加药) : OD values of wells containing both drugs and culture medium.
[0097] A (空白) : OD value of the well containing culture medium only.
[0098] A (0加药) : OD value of the wells without drug added to the cells.
[0099] The survival rates of RAW264.7 cells were shown in Table 2 after they were co-incubated with different preparations including Blank Gel, LND, HSN, LND+HSN, LP, HP, L-PMs, H-PMs, L / H-PMs, L / H-PMs@Gel and LP / HP / L / H-PMs@Gel at different concentrations for 24 h, 48 h and 72 h, respectively. Figure 6 shown.
[0100] Depend on Figure 6 A shows that after RAW264.7 cells were co-incubated with different preparations for 24 hours, when the preparation concentration was 20 μg / mL, there was no significant difference compared with the LND+HSN group. As the preparation concentration increased, this difference became increasingly obvious. When the preparation concentration was 160 μg / mL, the survival rate of the LP / HP / L / H-PMs@Gel group was significantly higher than that of the LND+HSN group ( **** P<0.0001). Compared with the free drug groups (LND group and HSN group), the cell survival rates of the preparation groups (L / H-PMs group and L / H-PMs@Gel group) were also significantly increased. Figure 6 As shown in B, after 48 h of co-incubation, the cell survival rates in the LP / HP / L / H-PMs@Gel group and the L / H-PMs@Gel group were significantly higher than those in the LND+HSN group ( **** P<0.0001). Figure 6 As shown in C, after 72 h of co-incubation, when the concentration of the preparation was higher than 40 μg / mL, the cell survival rate of the preparation group was significantly higher than that of the LND+HSN group ( ** P<0.01, *** P < 0.001, **** P<0.0001).
[0101] After 24h and 72h of co-incubation, the cell survival rate of the free drug combination group (LND+HSN group) was higher than that of the single free drug group (LND group, HSN group), and the difference became more obvious with the increase of concentration, which indicated that the combined use of free drugs could reduce the dosage of single drugs and reduce drug cytotoxicity. Compared with the single free drug group (LND group, HSN group), the cell survival rate of the two pH-sensitive prodrugs modified with PEG was significantly increased, which may be due to the characteristics of PEG avoiding reticuloendothelial system clearance and macrophage phagocytosis. With the increase of preparation concentration and the extension of co-incubation time, the difference of cell survival rate between each preparation group and LND+HSN group became more significant, which indicated that polymer micelles and injectable hydrogels as drug carriers could significantly reduce drug cytotoxicity. As for the LP / HP / L / H-PMs@Gel group, the cell survival rate did not change much with the changes of preparation concentration and co-incubation time.
[0102] 3. In vitro cytokine level detection
[0103] The concentration is 2×10 5 cells / mL of normal mouse RAW264.7 cell suspension, 100 μL was inoculated in a 96-well plate, and cultured at 37 ° C, 5% CO2. After the cells adhered, 100 μL of different preparations (LND, HSN, LND+HSN, LP, HP, LP+HP, L-PMs, H-PMs, L / H-PMs, L / H-PMs@Gel, LP / HP / L / H-PMs@Gel, BlankGel) were added to make the final concentration 80 μg / mL. At the same time, a Control group (without samples and enzyme-labeled reagents) was set up, and 3 replicates were set for each group of preparations. After incubation for 24 hours, the cell culture supernatant was collected, centrifuged at 1000×g for 3 minutes, and the supernatant was collected. The levels of IL-10 and IL-12 were detected using ELISA kits.
[0104] The results of the effects of each group of preparations on the content of IL-10 and IL-12 are as follows Figure 7 As shown. Figure 7 A shows that compared with the Control group (without samples and enzyme-labeled reagents), the IL-10 content of each group of preparations containing HSN and LND increased to varying degrees; among them, the IL-10 level of the API combination group and the final preparation group increased significantly ( **** P<0.0001). Figure 7 In B, compared with the Control group, the IL-12 levels of the preparations containing HSN and LND decreased significantly, among which the IL-12 levels of the API combination group and the final preparation group decreased most significantly ( ****P<0.0001). The contents of IL-12, a marker of M1-type RAW264.7 cells, and IL-10, a marker of M2-type RAW264.7 cells, changed under the influence of each group of preparations. Since HSN contained in the final preparation LP / HP / L / H-PMs@Gel has the effect of inhibiting proinflammatory cytokines and promoting M2 polarization of macrophages, LND has the effect of reducing the level of proinflammatory cytokines; the level of proinflammatory cytokine IL-12 in the final preparation group was significantly reduced, and the level of anti-inflammatory cytokine IL-10 was significantly increased, which preliminarily showed that it has a strong in vitro anti-inflammatory effect.
[0105] 4. Chicken embryo allantoic membrane experiment
[0106] (1) Chicken embryo incubation
[0107] After cleaning and disinfecting the fresh eggs, place them in the egg tray with the big end facing up and tilted at 60°±5°, then transfer the eggs to a constant temperature incubator and incubate them at 37°C and 55% humidity. Turn the eggs over and adjust their position 3 to 5 times a day. After 7 days of incubation, select the well-developed chicken embryos, mark the air chambers, and eliminate the weak sperm and dead sperm eggs.
[0108] (2) Preparation of pseudo-gas chamber
[0109] In a biological clean safety cabinet, clean the egg with alcohol cotton and wait for it to dry naturally. Then use a sterile needle to make a small hole with a diameter of about 2 mm in the middle of the egg (only the eggshell is damaged without damaging the shell membrane), and then make a small hole of similar size at the end of the air chamber (damaging the eggshell and shell membrane at the same time). Subsequently, a small amount of sterile saline is dripped into the small hole in the middle of the egg, and the chorioallantoic membrane is compressed by the saline to form a false air chamber. Seal the false air chamber, adjust the angle of the egg, so that the false air chamber of the egg is at the highest point of the egg, and continue to incubate in this state for 2 days.
[0110] (3) Open window and add medicine
[0111] In the biosafety cabinet, use tweezers to remove the transparent tape outside the false air chamber and cut out a 1 cm 2The eggshell, shell membrane and air chamber membrane were removed from the area to expose the chorioallantoic membrane of the chick embryo. The successfully windowed eggs were randomly divided into 15 groups, with 3 eggs in each group, namely LND, HSN, LND+HSN, LP, HP, LP+HP, L / H-PMs, Blank PMs, Blank Gel, L / H-PMs@Gel, LP / HP@Gel, LP / L / H-PMs@Gel, HP / L / H-PMs@Gel, LP / HP / L / H-PMs@Gel and saline group. Avoid the two main blood vessels and drip different preparations into the corresponding chick embryo chorioallantoic membrane. After sealing the dosing window with sterile transparent tape, carefully put it back into the incubator and continue incubation for 24 hours.
[0112] (4) Sample production
[0113] After 24 hours of incubation, slowly peel off the transparent tape and drip about 2 mL of the prepared fixative (methanol: acetone = 1: 1) into the dosing window to quickly fix the blood vessels and harden the chorioallantoic membrane tissue. After fixation for about 3 minutes, gently prick the chorioallantoic membrane blood vessels with a needle to confirm whether they are coagulated. After the blood vessels are completely coagulated, use dissection tools to peel off the blood vessels and the surrounding chorioallantoic membrane tissue, put the separated blood vessels and tissues into a culture dish containing PBS for development, wash to remove impurities, and transfer to a slide. Use an inverted microscope to observe and take pictures of the blood vessels, and compare the growth inhibition of new blood vessels by different preparations.
[0114] Depend on Figure 8 A shows that compared with the vascular status of the Saline group, the blood vessels of the LND group, L / H-PMs group, L / H-PMs@Gel group, LP / L / H-PMs@Gel group, HP / L / H-PMs@Gel group, and LP / HP / L / H-PMs@Gel group, which are preparations that can release free LND, are sparsely distributed and small in number, indicating that LND and its related preparations have an inhibitory effect on the growth of new blood vessels in the chick embryo chorioallantoic membrane. Figure 8 As shown in B and 8C, compared with the Saline group, the number of new blood vessels in the LP / HP / L / H-PMs@Gel group was significantly reduced ( **** P<0.0001, the vascular area ratio was significantly decreased ( **** P<0.0001), showing a significant inhibitory effect on the growth of new blood vessels.
[0115] 5. Cellular uptake experiment
[0116] RAW264.7 cells in the logarithmic growth period were adjusted to a concentration of 2×10 5cells / mL of cell suspension. Place the slides in the culture plate in advance, add 1mL of cell suspension to each well, set up 3 parallel wells at the same time, transfer to the incubator for incubation, and after the cells adhere to the wall, add LPS to half of the wells to activate RAW264.7. After 24 hours, discard the original culture medium, wash three times with PBS, and then add 100μL of L / H-PMs, L / H-PMs@Gel, LP / HP / L / H-PMs@Gel dilutions labeled with coumarin-6 green fluorescence and 900μL of blank culture medium, incubate for 2 hours, discard the culture medium and wash three times with PBS, fix with 4% paraformaldehyde for 10 minutes, discard the liquid and wash three times with PBS, then add DAPI staining for 3 minutes, discard the liquid and wash with PBS, take out the cell slides and seal with 50% glycerol, and observe the uptake of different fluorescent labeled preparations by RAW264.7 cells in different states using laser confocal microscopy.
[0117] Normal RAW264.7 cells and LPS-stimulated M1 RAW264.7 cells were incubated with L / H-PMs, L / H-PMs@Gel and LP / HP / L / H-PMs@Gel for different time periods. Fig. 9 As shown in A and 9B. As can be seen from the figure, with the extension of the co-incubation time, the uptake of the same preparation by the two phenotypes of RAW264.7 cells gradually increased; and the dual-effect polymer micelle composite hydrogel LP / HP / L / H-PMs@Gel can be more efficiently taken up by normal RAW264.7 cells and M1 RAW264.7 cells. After 4 hours of co-incubation, normal RAW264.7 cells began to take up three different preparations; and at 2 hours, the green fluorescence of the preparations could be clearly observed in the M1 RAW264.7 cells. Fig. 9 As shown in C and 9D, normal RAW264.7 cells and M1 RAW264.7 cells were incubated with the three preparations, and the fluorescence uptake was semi-quantitatively analyzed using Image pro plus. The results showed significant differences ( #### P < 0.0001), indicating that the uptake of the three preparations by both cells was time-dependent. At the same time point, the fluorescence uptake of the dual-effect polymer micelle composite hydrogel LP / HP / L / H-PMs@Gel by RAW264.7 cells also increased significantly ( * P<0.05, ** P<0.01, *** P < 0.001 and **** P<0.0001).
[0118] Experimental Example 2: Pharmacokinetics and in vivo distribution of dual-effect polymer micelle composite hydrogel
[0119] The SPF male SD rats required for this experiment were purchased from the Experimental Animal Center of Southwest Medical University (Luzhou, China, Certificate No. syxk2013-065) and kept in an SPF animal room. All animal-related experiments have been approved by the Animal Ethics Committee of Southwest Medical University (approval number: SWMU20220058) and were strictly carried out in accordance with the experimental animal management regulations of Southwest Medical University.
[0120] 1. Establishment of collagen-induced RA model in SD rats
[0121] In this experiment, male SD rats weighing about 220g were used to establish a collagen-induced arthritis (CIA) rheumatoid arthritis model. The mixed emulsion was subcutaneously injected at the base of the tail at a dose of 100μL / rat on day 0 after the adaptation period and on day 7 after the first immunization. During the first immunization, an equal volume mixed emulsion of bovine type II collagen and complete Freund's adjuvant (CFA) was injected; during the second immunization, an equal volume mixed emulsion of bovine type II collagen and complete Freund's adjuvant (CFA) was injected. On the 16th day after the first immunization, the arthritis index of the modeled rats was scored according to Table 6, and those with a score higher than 4 points were considered to be successful models.
[0122] 2. Calculation of pharmacokinetic parameters
[0123] Fifteen SD rats with successful modeling were randomly selected and divided into five groups (LND+HSN, LP+HP, L / H-PMs, L / H-PMs@Gel, LP / HP / L / H-PMs@Gel), with 3 rats in each group. The rats were injected intra-articularly at a dose of (0.5mg LND+0.5mg HSN) / kg. Blood was collected from the heart at 0.5h, 1h, 2h, 4h, 8h, 12h, 24h, 48h and 72h after administration, and centrifuged at 2500×g for 3min. The plasma was processed and passed through the membrane and then sampled and analyzed. The chromatographic peak areas of lenalidomide and hesperidin were recorded respectively. According to the two standard curves, the concentrations of the two drugs in each preparation group were calculated respectively. The pharmacokinetic parameters of LND and HSN were analyzed by DAS 3.0 software after intra-articular injection of LND+HSN, LP+HP, L / H-PMs, L / H-PMs@Gel, and LP / HP / L / H-PMs@Gel. The drug concentrations of lenalidomide and hesperidin in plasma after intra-articular injection of each group of preparations are shown in the figure. Fig.10 shown.
[0124] Depend on Fig.10A shows that LND in the free raw material drug group reaches its peak at about 2h, and the peak time of LND in the free dual-effect prodrug group and each preparation group is delayed to varying degrees. After PEG modification, the release rate of LND in the dual-effect prodrug group is slowed down by the release pH; and the encapsulation of the polymer gel and the effect of the hydrogel both slow down the release of LND. Among them, the dual-effect polymer micelle composite hydrogel combines the combined effects of the three, making the sustained release of LND the most significant. Similarly, Fig.10 As shown in B, the release of HSN in each group of preparations was similar to the release pattern of LND.
[0125] As shown in Tables 3 and 4, compared with the API combination group LND+HSN, the half-life T 1 / 2z , area under the drug-time curve AUC 0-t and average residence time MRT 0-t There was a significant increase ( * P<0.05, *** P < 0.001, **** P<0.0001), indicating that the dual effects of polymer micelles and hydrogels can increase the circulation time of LND and HSN in vivo.
[0126] Table 3 Pharmacokinetic parameters of LND in plasma of CIA model rats after intra-articular injection of each group of preparations
[0127]
[0128] Table 4 Pharmacokinetic parameters of HSN in plasma of CIA model rats after intra-articular injection of each group of preparations
[0129]
[0130] 3. Fluorescence labeling method to investigate the distribution in vivo
[0131] L / H-PMs, L / H-PMs@Gel and LP / HP / L / H-PMs@Gel were labeled with fluorescent dye DiR. Free DiR, L / H-PMs, L / H-PMs@Gel and LP / HP / L / H-PMs@Gel were injected into the joint cavity of CIA model rats at a dose of 5μg / rat. The in vivo distribution of each group of preparations at 0.5h, 4h, 8h and 12h was observed using a small animal in vivo imaging device. 12h after the injection, the SD rats in each group were killed, and the visceral tissues and hind limb joints were quickly dissected and separated, and photographed and analyzed using a small animal in vivo imaging device.
[0132] The distribution results of each group of fluorescent preparations in CIA model rats are as follows Fig.11Compared with the Blank group, the other fluorescent preparation groups showed obvious fluorescence in vivo after intra-articular injection. Fig.11 A shows that after intra-articular injection, the fluorescence intensity in the joint cavity gradually weakened over time. The fluorescence elimination rate of the free DiR group was the fastest; the fluorescence elimination rates of the polymer micelle group L / H-PMs and the polymer micelle-hydrogel complex group L / H-PMs@Gel were second; and the fluorescence elimination rate of the target drug delivery system dual-effect polymer micelle complex hydrogel LP / HP / L / H-PMs@Gel was the slowest.
[0133] 12 hours after administration, the in vitro fluorescence results of visceral tissues and joint cavities were as follows Fig.11 B. Among the fluorescent preparation groups, the fluorescence in the hind limb joint cavity was the most obvious; the fluorescence intensity of the target drug delivery system LP / HP / L / H-PMs@Gel group was the strongest. The semi-quantitative results of the in vivo and in vitro fluorescence intensity of each group of preparations are shown in Fig.11 As shown in C and 11D, 4h, 8h and 12h after administration, compared with the Blank group, the fluorescence of the LP / HP / L / H-PMs@Gel group was the highest, the decreasing trend was the slowest, and the fluorescence retention in the ex vivo joint cavity was the highest. The above fluorescence qualitative and quantitative results were consistent, indicating that the dual-effect polymer micelle composite hydrogel had a good sustained release effect in the joint cavity, and the porous structure of the hydrogel could increase the retention time of nanomedicine and dual-effect prodrug in the joint cavity.
[0134] Experimental Example 3: In vivo pharmacodynamic study
[0135] The SPF male SD rats required for this experiment were purchased from the Experimental Animal Center of Southwest Medical University (Luzhou, China, Certificate No. syxk2013-065) and kept in an SPF animal room. All animal-related experiments have been approved by the Animal Ethics Committee of Southwest Medical University (approval number: SWMU20220058) and were strictly carried out in accordance with the experimental animal management regulations of Southwest Medical University.
[0136] 1. Experimental animal grouping and drug administration scheme design
[0137] Fifty CIA model rats were randomly divided into 10 groups, 5 rats in each group; 5 healthy rats were randomly selected as the normal control group, and the grouping is shown in Table 5. The corresponding drugs of each group were injected into the joint cavity (3 days / time) starting from the 16th day after the initial immunization, and the administration was stopped on the 34th day after the initial immunization.
[0138] Table 5 Grouping of experimental animals
[0139]
[0140]
[0141] 2. Investigation of treatment effect
[0142] (1) Status Change
[0143] After the initial immunization, we began to observe and record indicators such as the activity level, food and water intake, coat color changes, and joint pathological changes of SD rats in each group. During the adaptive feeding period before modeling and grouping, the SD rats were able to maintain normal food and water intake and were in a good mental state. After modeling and grouping, the SD rats in each group had redness, swelling, and pain in the ankle joints, and their food and water intake decreased, showing symptoms such as rapid breathing, poor mental state, loss of appetite, and loose stools. After the last dose of medication, the hind limbs of the rats in the Saline group and the Blank Gel group were still red and swollen, while the symptoms of the rats in the other drug treatment groups were alleviated to varying degrees. Fig.12 A shows that the redness and swelling of the hind limbs of rats in the LP / HP / L / H-PMs@Gel group were alleviated most significantly.
[0144] (2) Weight changes
[0145] Starting from the 16th day after the initial immunization, the body weight of SD rats was measured (3 days / time) to observe the changes in body weight of rats in each group after intra-articular injection. Fig.12 As shown in B, the body weight of rats in the Saline group and Blank Gel group gradually decreased as the disease worsened; the body weight of healthy rats increased slowly over time. Compared with the Saline group, the body weight of rats in the other drug treatment groups showed a trend of first decreasing and then gradually increasing; the body weight of rats in the LP / HP / L / H-PMs@Gel group increased significantly (****P<0.0001).
[0146] (3) Changes in foot volume
[0147] Starting from the 16th day after the initial immunization, the volume of the left hind limb of SD rats was measured (3 days / time), and the measurement was repeated 3 times. Fig.12 As shown in Figure C, the paw volume of healthy rats did not change significantly, while the paw volume of rats in the Saline group and Blank Gel group showed a continuous growth trend due to the lack of drug treatment. Starting from the 22nd day after the first immunization, the paw volume of rats in most drug treatment groups gradually decreased. After the last administration, the paw volume of rats in the LP / HP / L / H-PMs@Gel group was closest to that of healthy rats, and the treatment effect was the most significant ( *** P<0.001).
[0148] (4) Changes in ankle diameter
[0149] Starting from the 16th day after the initial immunization, the ankle diameter of the left hind limb of the rats was measured (3 days / time), and the measurement was repeated 3 times. The changes in ankle diameter of rats in each group are as follows Fig.12As shown in D, the ankle diameter of healthy rats did not change significantly, while the ankle diameter of rats in the Saline group and Blank Gel group continued to increase significantly due to joint swelling. Compared with the Saline group, the ankle swelling of rats in each drug treatment group was reduced, and the ankle diameter gradually decreased after the third administration. However, the ankle diameter of rats in the LP / HP / L / H-PMs@Gel group gradually decreased significantly after the first administration ( ** P<0.01). After the last administration, the ankle joint swelling of the rats in the LP / HP / L / H-PMs@Gel group was significantly reduced, and the ankle joint diameter of the rats in the LP / HP / L / H-PMs@Gel group had decreased to a level close to that of the rats in the healthy group, showing a significant therapeutic effect.
[0150] (5) Arthritis Index Score
[0151] After each intra-articular injection, the arthritis index (AI) of each group of SD rats was scored according to Table 6. The sum of the scores of the four limbs was the final AI score of each rat, and the highest score was 16 points.
[0152] Table 6 Scoring criteria for rat arthritis index
[0153]
[0154] The arthritis index scores of rats in each group are shown in Figure 12E. The scores of rats in the healthy group were all 0, and the scores of rats in the Saline group and Blank Gel group gradually increased over time. Except for the HSN group, the scores of rats in the drug treatment groups showed a trend of increasing first and then decreasing. Among them, the scores of rats in the LP / HP / L / H-PMs@Gel group were closest to those in the healthy group after the scores decreased, indicating that LP / HP / L / H-PMs@Gel had a significant therapeutic effect (****P<0.0001).
[0155] 3. Determination of spleen and thymus coefficients
[0156] One hour after the last administration, the experimental rats in each group were anesthetized and killed, and the spleen and thymus were removed after dissection. After washing with physiological saline, excess water was absorbed with filter paper and their weights were accurately weighed. According to the weight of the rats and the weight of each immune organ, the immune organ coefficients were calculated in combination with formulas 4 and 5.
[0157] Spleen coefficient (%) = spleen mass (mg) / body weight (g) × 100% (Formula 4)
[0158] Thymus coefficient (%) = thymus mass (mg) / body weight (g) × 100% (Formula 5)
[0159] The results of spleen coefficient and thymus coefficient are as follows Fig.13As shown in A and 13B. Since RA is an autoimmune disease, it will cause spleen and thymus hyperplasia, thereby increasing the spleen coefficient and thymus coefficient. Compared with healthy rats, the immune organ coefficients of rats in the Saline group and Blank Gel group were significantly increased; after intra-articular injection of the drug in the other drug treatment groups, the spleen and thymus coefficients were reduced to varying degrees. Among them, the immune organ coefficient of rats in the LP / HP / L / H-PMs@Gel group decreased most significantly ( #### P < 0.0001, *** P<0.001).
[0160] 4. Hepatotoxicity evaluation
[0161] One hour after the last administration, blood was collected from the hearts of rats in each group and centrifuged at 850×g for 15 min to collect serum. The levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in serum were detected using a veterinary biochemical analyzer.
[0162] The ALT and AST test results of rats in each group were as follows Fig.13 C and 13D. Compared with healthy rats, the ALT and AST levels of rats in the three raw material drug groups, LND+HSN group, LND group and HSN group, were at higher levels, indicating that the two raw material drugs had certain hepatotoxicity. Compared with the free raw material drug group, the ALT and AST levels of rats in the LP / HP / L / H-PMs@Gel group were significantly reduced ( **** P < 0.0001), which indicates that the hepatotoxicity of the raw drug was significantly reduced after being encapsulated by polymer micelles and hydrogel 3D structures.
[0163] 5. Cytokine level detection
[0164] One hour after the last administration, blood was collected from the heart of the rats in each group and centrifuged at 800×g for 20 min to collect serum. The levels of pro-inflammatory cytokines such as IL-1β and TNF-α in the serum of SD rats in each group were determined by enzyme-linked immunosorbent assay.
[0165] The results of the determination of IL-1β and TNF-α levels in the serum of rats in each group are as follows Fig.13 E and 13F. Compared with healthy rats, the levels of pro-inflammatory cytokines in the serum of rats in the Saline group and Blank Gel group were at higher levels due to the lack of drug treatment. Compared with the Saline group, the levels of IL-1β and TNF-α in the serum of rats in each drug treatment group showed a decreasing trend to varying degrees. Among them, the levels of IL-1β and TNF-α in the serum of rats in the LP / HP / L / H-PMs@Gel group were significantly reduced ( ####P<0.0001). Compared with other drug treatment groups, LP / HP / L / H-PMs@Gel showed significant anti-inflammatory effects ( *** P<0.001).
[0166] 6. Micro-CT Scanning
[0167] One day after the last administration, the rats in each group were anesthetized and killed, and the hind limbs were removed, the muscles and fascia tissues were stripped, and the leg bones of the hind limbs were placed in 4% paraformaldehyde fixative and stored at room temperature overnight. A high-resolution Micro-CT analyzer (Skyscan1172, Bruker Corporation, Beijing) was used to analyze the changes in pathological characteristics such as bone erosion in the leg bones of the rats in each group.
[0168] After intra-articular injection of drugs, the Micro-CT scan results of the hind limbs of rats in each group were as follows: Fig.14 As shown. Fig.14 A shows that the hind limb leg bones of rats in the Saline group and Blank Gel group had obvious bone destruction. Under the action of the preparations of each drug treatment group, the degree of bone destruction was alleviated to varying degrees. Compared with the free drug, the dual-drug combination group had a better effect; the degree of bone destruction reversal in the polymer micelle group and the dual-effect prodrug gel group was more obvious. The dual-effect polymer micelle composite hydrogel LP / HP / L / H-PMs@Gel significantly reduced the area of bone damage, reversed bone destruction, and had the most significant therapeutic effect on rheumatoid arthritis.
[0169] Results of bone-related quantitative detection indicators are as follows Fig.14 (BG) shown. Fig.14 B, 14C, 14E, and 14G show that compared with the Saline group and Blank Gel, the bone density, trabecular thickness, trabecular number, and bone-tissue volume ratio of each treatment drug group increased to varying degrees. Among them, the changes in the indicators of LP / HP / L / H-PMs@Gel were the most obvious ( #### P<0.0001). Fig.14 D and 14F are the results of trabecular spacing and bone surface area to bone volume ratio in each group. Compared with the Saline group, the data of each drug-treated group showed a decreasing trend to varying degrees; the two indicators of LP / HP / L / H-PMs@Gel changed most significantly ( #### P<0.0001). The quantitative detection results were consistent with the Micro-CT scanning results.
[0170] Finally, it should be noted that the terms "comprises," "comprising," or any other variation thereof are intended to cover non-exclusive inclusion, such that a process, method, article, or device comprising a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process, method, article, or device. Although preferred embodiments of the present invention have been described, additional changes and modifications may be made to these embodiments by those skilled in the art once the basic creative concepts are known. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the present invention.
Claims
1. A method for preparing a dual-effect polymer micelle composite hydrogel, It is characterized in that The method comprises: S1. Chemically linking the lenalidomide API and the hesperidin API with terminal-modified polyethylene glycol, respectively, to obtain PEG-modified lenalidomide LND-PEG and PEG-modified hesperidin HSN-PEG, respectively, and dissolving the LND-PEG and HSN-PEG together in dichloromethane to obtain a prodrug mixed solution; S2, dissolving the lenalidomide API and the hesperidin API in dichloromethane to obtain a drug solution; dissolving mPEG2000-PLA2000 in dichloromethane to obtain a carrier solution; mixing the drug solution and the carrier solution, and performing an emulsification self-assembly reaction in a water bath at 38-42° C. to obtain a dual-drug loaded micelle solution L / H-PMs; S3, after the prodrug mixed solution and the dual-drug loaded micelle solution are mixed, β-sodium glycerophosphate is added to dissolve, thereby obtaining a β-sodium glycerophosphate mixed solution; S4, adding the β-sodium glycerophosphate mixed solution dropwise to the chitosan solution after ice bathing to obtain a gel-like dual-effect polymer micelle composite hydrogel LP / HP / L / H-PMs@Gel.
2. The preparation method according to claim 1, It is characterized in that The water bath heating reaction time is 10 to 14 hours.
3. The preparation method according to claim 1, It is characterized in that The drug solution and the carrier solution are mixed and then subjected to an emulsified self-assembly reaction in a water bath at 38 to 42° C., comprising: the drug solution and the carrier solution are mixed and then dropwise added to ultrapure water heated to 38 to 42° C. in a water bath for reaction.
4. The preparation method according to claim 1, It is characterized in that The mass fraction of the chitosan solution is 1-3%.
5. The preparation method according to claim 1, It is characterized in that The mass ratio of the sodium β-glycerophosphate to the mPEG2000-PLA2000 is 2.5-3.5:
1.
6. The preparation method according to claim 1, It is characterized in that The ice bath time of the β-sodium glycerophosphate mixed solution is 8 to 20 minutes.
7. The preparation method according to claim 1, It is characterized in that The volume ratio of the sodium β-glycerophosphate mixed solution to the chitosan solution is 1:2.5-3.
5.
8. A dual-effect polymer micelle composite hydrogel prepared by the method according to any one of claims 1 to 7.
9. Use of the dual-effect polymer micelle composite hydrogel according to claim 8 in the preparation of a drug for treating rheumatoid arthritis.
Citation Information
Patent Citations
Thiolated chitosan / gelatin / beta-sodium glycerophosphate composite hydrogel and preparation method thereof
CN110339155A
Response surface method optimization-based flurbiprofen axetil long-circulating lipid microspheres as well as preparation process and application thereof
CN114191390A
Fatty acid lenalidomide and their uses
US20120283292A1
Micelar delivery system based on enzyme-responsive amphiphilic peg-dendron hybrid
US20170348430A1
Transdermal Drug Delivery Systems for Administration of a Therapeutically Effective Amount of Lenalidomide and Other Immunomodulatory Agents
US20220395468A1
